learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
forLearn
1 / 1 resultsResearch
5 / 860 resultsresearch Expression of Hair-Related Keratins in a Soft Epithelium: Subpopulations of Human and Mouse Dorsal Tongue Keratinocytes Express Keratin Markers for Hair, Skin, and Esophageal Types of Differentiation
Hoxc13 is important for hair and tongue development by controlling hair keratin genes.
research Characterization of an In Vivo Model for the Study of Eyelash Biology and Trichomegaly: Mouse Eyelash Morphology, Development, Growth Cycle, and Anagen Prolongation by Bimatoprost
The study showed that mouse eyelashes can be used to study eyelash growth and that bimatoprost makes them longer and more numerous.
research Fine Structure and Immunocytochemistry of Monotreme Hairs, with Emphasis on the Inner Root Sheath and Trichohyalin-Based Cornification During Hair Evolution
Monotreme hair structure and protein distribution are similar to other mammals, but their inner root sheath cornifies differently, suggesting a unique evolution from reptile skin.
research Osteopontin Gene Is Expressed in the Dermal Papilla of Pelage Follicles in a Hair-Cycle-Dependent Manner
The osteopontin gene is active in a specific part of rat hair follicles during a certain hair growth phase and might affect hair cycle and diseases.
research NF-κB Participates in Mouse Hair Cycle Control and Plays Distinct Roles in Various Pelage Hair Follicle Types
NF-κB is crucial for different stages and types of hair growth in mice.
Community Join
5 / 134 resultscommunity Will Pelage include Norwood 7 hair loss in PP405 phase 3 trials to see its true regenerative potential?
Norwood 7 hair loss is often excluded from trials to ensure treatments appear more effective and to reduce costs. Some believe treatments effective for Norwood 5 could work on Norwood 7, but companies prioritize market readiness.
community Pelage Announces Positive Results of Phase 2a Trials for PP405
PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.
community It's the year 2050 and we are still waiting for Pelage to release the full phase 2 results of PP405 and start phase 3.
Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.
community Quote from Pelage (PP-405) Spokesperson...
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
community Pelage, PP405, is creating a database for potential new trial volunteers
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.